

**March 2015 PBAC MEETING – OTHER MATTERS**

<b>DRUG TYPE OR USE</b>	<b>PURPOSE</b>	<b>PBAC OUTCOME</b>
Biosimilar medicines	<p>The PBAC considered the marking as equivalent (i.e. “a” flagging) in the Schedule of Pharmaceutical Benefits (the Schedule) of a biosimilar medicine with its reference medicine.</p> <p>Note: the reference medicine is the medicine against which the new medicine has demonstrated biosimilarity.</p>	<p>The PBAC indicated it would consider the marking of equivalent (i.e. “a” flagging) in the Schedule of Pharmaceutical Benefits (the Schedule) of biosimilar medicines with their reference medicine on a case by case basis, taking into account the evidence presented in each submission to list a biosimilar medicine.</p> <p>The PBAC further considered PBS subsidy of biosimilar medicines at its special meeting on 17 April 2015. The outcomes of that meeting will be published separately.</p>